Clinical Trials on High-Risk Prostate Cancer in Australia
Total 268 results
-
Novartis PharmaceuticalsCompletedProstate CancerSaudi Arabia, Taiwan, Korea, Republic of, Lebanon, Brazil, China, New Zealand, Australia, Thailand, Kuwait
-
CelgeneCompletedProstate CancerUnited States, Spain, France, Belgium, Australia, Denmark, Austria, United Kingdom, Netherlands, Poland, Israel, Italy, Germany, Greece, Canada, Czechia, Hungary, Mexico, Russian Federation, South Africa, Sweden
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate CancerCanada, United States, Spain, Australia, Denmark, Korea, Republic of, Belgium, Singapore, Finland, Netherlands, France, Austria, Germany, Israel, United Kingdom, Italy, Japan, Lithuania, Poland, Russian Federation, Slovakia, Sweden
-
Astellas Pharma Europe Ltd.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedMetastatic Castration Resistant Prostate CancerBelgium, France, Spain, Austria, Czechia, Germany, Greece, Italy, Netherlands, Norway, Poland, Russian Federation, Sweden, Switzerland, Turkey, United Kingdom
-
pharmaand GmbHFoundation MedicineActive, not recruitingMetastatic Castration Resistant Prostate CancerUnited States, Canada, Spain, France, Australia, Ireland, Belgium, Denmark, United Kingdom, Germany, Israel, Italy
-
Janssen Research & Development, LLCRecruitingMetastatic Castrate-sensitive Prostate CancerUnited States, France, Mexico, Germany, Australia, Brazil, Canada, China, Poland
-
Merck Sharp & Dohme LLCOrion Corporation, Orion PharmaRecruitingProstatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)Australia, Germany, United States, Puerto Rico, Israel, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain, France, Hong Kong, Portugal, Romania, Chile, Czechia, Hungary, Italy, Sweden, Turkey, United Kingdom, Estonia, Ir... and more
-
Novartis PharmaceuticalsCompletedAdvanced Triple Negative Breast Cancer (TNBC) With High TAMsFrance, Italy, Austria, Taiwan, United States, Spain, Australia, Korea, Republic of, Belgium, Germany, Hong Kong, Turkey
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingMetastatic Breast Cancer | Bone Metastases | Metastatic Prostate CancerSwitzerland, Germany, Austria
-
AstraZenecaActive, not recruitingHormone-Sensitive Prostate CancerUnited States, Belgium, Spain, Canada, Poland, Argentina, India, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Germany, Korea, Republic of, Brazil, Mexico, Peru, Philippines, China, United Kingdom, Hong Kong, Israel, ... and more
-
AstraZenecaRecruitingProstate CancerUnited States, Spain, United Kingdom, Netherlands, Canada, Australia
-
Myovant Sciences GmbHCompletedA Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO)Prostate CancerUnited States, Germany, Spain, New Zealand, Brazil, Belgium, Australia, Austria, Canada, China, Denmark, Finland, France, Italy, Japan, Korea, Republic of, Netherlands, Poland, Slovakia, Sweden, Taiwan, United Kingdom
-
University of SydneyMemorial Sloan Kettering Cancer Center; Bayer; Canadian Cancer Trials Group; Australian... and other collaboratorsActive, not recruitingProstate CancerUnited States, Canada, Australia, United Kingdom, New Zealand, Ireland
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.Active, not recruitingMetastatic Hormone Sensitive Prostate CancerKorea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
-
Prostate Cancer Clinical Trials ConsortiumRecruitingProstate CancerUnited States, Australia, Spain, Switzerland, United Kingdom, Kenya, Canada, Ireland, Barbados, Brazil, Jamaica, Nigeria, Norway, Sweden, South Africa
-
Active Biotech ABCompletedProstate CancerFrance, Poland, Ukraine, United Kingdom, United States, China, Germany, Taiwan, Spain, Belgium, Colombia, Israel, Bulgaria, India, Panama, Romania, Netherlands, Greece, Sweden, Korea, Republic of, Australia, Canada, Chile, New Zealand, ... and more
-
BayerOrion Corporation, Orion PharmaCompletedMetastatic Hormone-sensitive Prostate CancerBelgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
-
AstraZenecaTerminatedProstate CancerSweden, United States, Brazil, Czech Republic, France, Italy, Peru, Russian Federation, Spain, Turkey, United Kingdom, Germany, China, Hungary, Latvia, Poland, Romania, Japan, Finland, Norway, Canada, South Africa, Argentina, Australia, Belgiu... and more
-
LTN PHARMACEUTICALS, INC.TerminatedProstate CancerUnited States, France, Australia, Canada, Spain, United Kingdom, Italy, Belgium
-
Janssen Research & Development, LLCCompletedProstate CancerUnited States, Australia, France, United Kingdom, Belgium, Germany, Spain, Canada, Netherlands, Greece, Sweden
-
Millennium Pharmaceuticals, Inc.CompletedProstate CancerUnited States, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Belarus, Israel, Portugal, Bulgaria, Romania, South Africa, Japan, Switzerland, Canada, Australia, Netherlands, Greece, Chile, New Zealand, Peru, Singapore, Russian Federation and more
-
AstraZenecaCompletedProstate CancerSweden, United States, Brazil, Czech Republic, France, Russian Federation, United Kingdom, Germany, China, Hungary, Poland, Finland, Netherlands, Mexico, Hong Kong, Australia, Belgium, Canada, Denmark, Portugal, South Africa, Korea... and more
-
SanofiCompletedProstate CancerKorea, Republic of, Spain, United States, Argentina, Peru, Romania, Taiwan, United Kingdom, Belgium, Chile, Netherlands, Australia, Germany, Tunisia, Brazil, Canada, France, Hungary, Poland, Russian Federation, South Africa, Turkey
-
AstraZenecaCompletedProstate CancerSweden, United States, Australia, France, United Kingdom, Poland, Finland, Netherlands, Norway, Belgium, Canada, Indonesia, Denmark, Switzerland
-
SanofiCompletedProstate CancerAustralia, Portugal, Spain, Peru, Sweden, Romania, Russian Federation, Belarus, Israel, France, Italy, Denmark, Turkey, Germany, United States, Brazil, Canada, China, Czechia, Finland, Japan, Mexico, Poland, Taiwan, Ukraine
-
Janssen Pharmaceutica N.V., BelgiumCompletedProstate CancerFrance, Poland, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Slovenia, Turkey, Sweden, Austria, Russian Federation, Luxembourg, Switzerland
-
Gustave Roussy, Cancer Campus, Grand ParisNational Cancer Institute, FranceTerminatedVery High Risk NeuroblastomaItaly, Austria, France, Netherlands, Spain
-
zr Pharma & GmbHFoundation MedicineCompletedMetastatic Castration Resistant Prostate CancerUnited States, Spain, United Kingdom, France, Australia, Belgium, Denmark, Israel, Germany, Ireland, Canada, Italy
-
AstraZenecaRecruitingMetastatic Castration-Sensitive Prostate CancerUnited States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
-
Central European Cooperative Oncology GroupTerminatedProstate CancerMontenegro, Slovenia, Serbia, Russian Federation, Austria, Poland, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Lithuania, Romania, Slovakia, South Africa
-
Merck Sharp & Dohme LLCActive, not recruitingMetastatic Hormone-Sensitive Prostate CancerTaiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
-
Janssen Research & Development, LLCActive, not recruitingMetastatic Castration-sensitive Prostate CancerUnited States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG Oncology; Eastern Cooperative Oncology Group and other collaboratorsCompletedProstate CancerUnited States, Australia, Peru, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingGanglioneuroblastoma | High Risk NeuroblastomaUnited States, New Zealand, Australia
-
BayerActive, not recruitingHot Flashes | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerSpain, France, Belgium, United Kingdom, Hungary, Israel, Italy, Ireland, Germany, Portugal, Finland, Poland, Romania, Canada, Austria, Kazakhstan
-
Sunnybrook Health Sciences CentreExact ImagingRecruitingProstate CancerUnited States, Canada, Austria, France, Germany, Spain, Belgium
-
McMaster UniversityCanadian Cancer Society (CCS); Prostate Cancer CanadaRecruitingCardiovascular Disease | Prostate CancerUnited States, Canada, Australia, Brazil, Israel, Turkey, Colombia
-
PfizerMedivation, Inc.CompletedProstate CancerAustralia, United States, Spain, France, Korea, Republic of, Germany, Austria, United Kingdom, Belgium, Hungary, Italy, Brazil, Netherlands, Poland
-
Bristol-Myers SquibbAstellas Pharma Inc; Clovis Oncology, Inc.Active, not recruitingProstate CancerUnited States, Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Mexico, Spain
-
Novartis PharmaceuticalsCompletedAML and High Risk MDSGermany, Italy, France, Netherlands, United States, Australia, Japan
-
Bristol-Myers SquibbCompletedHigh Risk Stage III MelanomaItaly, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate CancerUnited States, Australia, Spain, United Kingdom, Denmark, Belgium, Slovakia, Finland, Italy, France, Sweden
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
SanofiCompletedBreast Cancer | Prostatic NeoplasmsAustralia
-
AmgenRecruitingProstate CancerJapan, United States, Korea, Republic of, Taiwan, Australia, Spain, Germany, Switzerland, China, Portugal
-
Kirby InstituteActive, not recruitingHigh Grade Squamous Intra-epithelial Lesion (HSIL)Australia
-
BayerActive, not recruitingProstate CancerUnited States, Canada, Japan, Spain, Germany, Belgium, Argentina, Austria, Brazil, Greece, Italy, Russian Federation, Taiwan, China, Denmark, France, Colombia
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)TerminatedPain | Breast Cancer | Prostate CancerUnited States, Australia, Peru, Puerto Rico
-
Xennials Therapeutics Australia Pty LtdPinotbio, Inc.TerminatedAdvanced Solid Tumor | High-grade Glioma | Platinum-Resistant Ovarian Cancer | Platinum-Resistant Urothelial CarcinomaAustralia